Abemaciclib with fulvestrant is in clinical development for the treatment of patients with hormone receptor positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) locally advanced or metastatic breast cancer with evidence of disease progression or recurrence following cyclin-dependant kinases (CDK) 4/6 inhibitor and endocrine therapy. Breast cancer is when abnormal cells in the breast begin to grow in an uncontrolled way and eventually form a tumour. Locally advanced breast cancer is where cancer has spread from the breast to areas close to the breast or to the chest wall. Metastatic breast cancer is where the cancer has spread to other parts of the body. HR+ breast cancer is a type of breast cancer that expresses either progesterone or oestrogen or both hormone receptors. HER2- breast cancers have low or no expression of the HER2 protein in cancer cells. Despite advances in the understanding of origin breast cancer, precise treatment of locally advanced HR+/HER2- breast cancer remains an unmet need.
Abemaciclib with fulvestrant for HR+/HER2- locally advanced or metastatic breast cancer after CDK4/6 inhibitor and endocrine therapy
Abemaciclib with fulvestrant is in clinical development for the treatment of patients with hormone receptor positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) locally advanced or metastatic breast cancer with evidence of disease progression or recurrence following cyclin-dependant kinases (CDK) 4/6 inhibitor and endocrine therapy. Breast cancer is when abnormal cells in the breast begin to grow in an uncontrolled way and eventually form a tumour.